JPMorgan initiates coverage of Arcus Biosciences with overweight rating, $41 target
RCUS•JPMorgan initiated coverage of Arcus Biosciences with an overweight rating and a $41 price target.
Related News
Xylem Inc: RBC cuts target price to $135 from $164
XYL•
Telix spotlights Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma at EANM congress
TLX•
BofA reportedly no longer in talks to arrange IPO of China's Moonshot AI
BAC•
Copper firms with focus on supply developments in Chile
FCX•
Honeywell Technologies: RBC cuts target price to $270 from $293
HON•